Drug Profile
Linavonkibart - Scholar Rock
Alternative Names: Linavonkibart; Niche modulators - Scholar Rock; SRK-181; SRT-BETA-1-AB3Latest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator Scholar Rock
- Class Antianaemics; Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Anaemia; Autoimmune disorders; Fibrosis; Musculoskeletal disorders
Most Recent Events
- 03 Nov 2023 Efficacy, pharmacodynamics and adverse events data from a phase I DRAGON trial in Solid tumours released by Scholar Rock
- 09 May 2023 SRK 181 is still in phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT04291079)
- 09 May 2023 SRK 181 is still in phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (Parenteral) (NCT04291079)